CLICK HERE FOR INVESTOR PORTAL
Hadean Ventures
Hadean Ventures
Hadean Ventures
  • HOME
  • TEAM
  • NEWS
  • PORTFOLIO
  • INVESTORS
  • IMPACT/ESG
  • EVENTS
  • CAREERS
  • CONTACT

    @hadeanventures

  • All
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • Current companies
  • Exited companies
  • News
  • Uncategorized
  • Ribbon Biolabs raises EUR 18 million in its Series A financing

    by @hadeanventures on January 31, 2022

    Ribbon Biolabs Raises EUR 18 Million Series A Financing

    Continue Reading
  • EMERGENCE THERAPEUTICS

    by @hadeanventures on December 15, 2021

    Emergence Therapeutics is a European biopharmaceutical company...

    Continue Reading
  • Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC

    by @hadeanventures on December 10, 2021

    Series A round led by Pontifax and includes new and existing investors Lead product is…

    Continue Reading
  • Hadean Ventures Announces the 1st Closing of EUR 90m for its Second Fund

    by @hadeanventures on September 27, 2021

    Hadean Ventures Announces the 1st Closing of EUR 90m for its Second Fund...

    Continue Reading
  • Cardior raises €64 M Series B to advance clinical pipeline of RNA therapeutics to treat Cardiac Disease

    by @hadeanventures on August 26, 2021

    Oversubscribed round enables late-stage clinical development of lead candidate, a micro-RNA-132 inhibitor, in heart failure…

    Continue Reading
  • Attgeno appoints Björn Westberg as CFO

    by @hadeanventures on July 8, 2021

    Attgeno appoints Björn Westberg as CFO Jul 08, 2021 05:00 UTC Attgeno AB announces today…

    Continue Reading
  • SAGA Diagnostics raises €10.5 million

    by @hadeanventures on June 29, 2021

    SAGA Diagnostics raises SEK 106 million (€10.5 million)...

    Continue Reading
  • Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round

    by @hadeanventures on June 29, 2021

    Norwegian radiopharmaceutical company announces successful closing of a private placement that will allow the company…

    Continue Reading
  • Gesynta Pharma announces significant progress across development program for first-in-class drug candidate GS-248

    by @hadeanventures on June 15, 2021

    Stockholm, Sweden, June 14 2021 Gesynta Pharma announces significant progress across development program for first-in-class…

    Continue Reading
  • Abliva reports positive clinical Phase 1a/b results for KL1333 including signs of efficacy in PMD patients

    by @hadeanventures on May 19, 2021

    Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of…

    Continue Reading
  • ←
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • →
  • HOME
  • TEAM
  • NEWS
  • PORTFOLIO
  • INVESTORS
  • IMPACT/ESG
  • EVENTS
  • CAREERS
  • CONTACT

What are you looking for?